News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Appili Announces Results Of 2017 AGM



9/8/2017 10:57:12 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, today announced the results of the Company's annual general meeting of shareholders (AGM) held on September 7, 2017.

During the AGM, the shareholders re-elected: Brian Bloom, Dr. John Holyoake, Dr. Lidija Marusic, Stephen Nicolle and Kevin Sullivan to serve on the Board of Directors until the next annual meeting of shareholders.

The shareholders approved all motions put forth at the meeting including the appointment of PricewaterhouseCoopers LLP, Chartered Accountants, as the Company's independent auditors.

About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat drug-resistant Gram-negative infections that are priority pathogens for the Centers for Disease Control and Prevention and the World Health Organization. For more information visit www.AppiliTherapeutics.com.

Appili Therapeutics
Media Relations:
Jennifer Cameron, 902-209-4704
Media@AppiliTherapeutics.com
or
Investor Relations:
Kimberly Stephens
CFO
Info@AppiliTherapeutics.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES